DOCSLIB.ORG

For People Taking BIKTARVY® Combination Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For People Taking BIKTARVY® Combination Tablets Introduction / Introduction of contents Table How to take BIKTARVY BIKTARVY take to How / Tablets Combination Eects For People Taking BIKTARVY® Combination Tablets Precautions Editorial Supervisor Takuma Shirasaka Director of AIDS Medical Center National Hospital Organization Osaka National Hospital What to do if you miss miss do if you to What a dose of BIKTARVY Tablets Combination Side eects Contact Information Gilead Sciences, Inc. Gran Tokyo South Tower, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616 BVY19DS0086PA Created in May 2019 Additional information Additional Introduction For People Taking BIKTARVY Combination Tablets Table of contents / Introduction of contents Table This leaflet was created for people who take BIKTARVY Combination Tablets. It includes information about the characteristics of BIKTARVY Combination Tablets, 1 Introduction how to take BIKTARVY Combination Tablets, what to do if you forget to take 3 What are BIKTARVY Combination Tablets? BIKTARVY Combination Tablets, the side eects of BIKTARVY Combination Tablets, and precautions for taking BIKTARVY Combination Tablets. Read this 5 For better treatment going forward How to take BIKTARVY BIKTARVY take to How / Tablets Combination Eects leaflet carefully before taking BIKTARVY Combination Tablets. 7 If you are taking other medicines The treatment of HIV (human immunodeficiency virus) infection is aimed at 8 Precautions for taking inhibiting the multiplication of HIV, thereby preventing the onset of AIDS. BIKTARVY Combination Tablets BIKTARVY Combination Tablets is one of the drugs called “anti-HIV medicines” Precautions that suppress the multiplication of HIV. 9 What should you do if you miss a dose of To safely achieve the adequate ecacy of an anti-HIV medicine, it is important to BIKTARVY Combination Tablets? take it correctly. 10 How to prevent missing a dose A medical decision needs to be made based on your own particular circumstances before starting the administration of BIKTARVY Combination Tablets. 11 Side eects of BIKTARVY Combination Tablets Listen carefully to the explanation provided by your healthcare provider (doctor, What to do if you miss miss do if you to What a dose of BIKTARVY Tablets Combination nurse, or pharmacist) and follow their instructions. 13 Is there anything else you should know? 13 Information sources concerning HIV infection If you have any questions about the administration of BIKTARVY Combination Tablets, consult your healthcare provider (doctor, nurse, or pharmacist). Side eects 1 2 information Additional Introduction For People Taking BIKTARVY Combination Tablets Table of contents / Introduction of contents Table This leaflet was created for people who take BIKTARVY Combination Tablets. It includes information about the characteristics of BIKTARVY Combination Tablets, 1 Introduction how to take BIKTARVY Combination Tablets, what to do if you forget to take 3 What are BIKTARVY Combination Tablets? BIKTARVY Combination Tablets, the side eects of BIKTARVY Combination Tablets, and precautions for taking BIKTARVY Combination Tablets. Read this 5 For better treatment going forward How to take BIKTARVY BIKTARVY take to How / Tablets Combination Eects leaflet carefully before taking BIKTARVY Combination Tablets. 7 If you are taking other medicines The treatment of HIV (human immunodeficiency virus) infection is aimed at 8 Precautions for taking inhibiting the multiplication of HIV, thereby preventing the onset of AIDS. BIKTARVY Combination Tablets BIKTARVY Combination Tablets is one of the drugs called “anti-HIV medicines” Precautions that suppress the multiplication of HIV. 9 What should you do if you miss a dose of To safely achieve the adequate ecacy of an anti-HIV medicine, it is important to BIKTARVY Combination Tablets? take it correctly. 10 How to prevent missing a dose A medical decision needs to be made based on your own particular circumstances before starting the administration of BIKTARVY Combination Tablets. 11 Side eects of BIKTARVY Combination Tablets Listen carefully to the explanation provided by your healthcare provider (doctor, What to do if you miss miss do if you to What a dose of BIKTARVY Tablets Combination nurse, or pharmacist) and follow their instructions. 13 Is there anything else you should know? 13 Information sources concerning HIV infection If you have any questions about the administration of BIKTARVY Combination Tablets, consult your healthcare provider (doctor, nurse, or pharmacist). Side eects 1 2 information Additional What are BIKTARVY Combination Tablets? / Introduction of contents Table BIKTARVY is a medicine for HIV infection that suppresses the multiplication of the virus in the blood1). Eects of BIKTARVY Combination Tablets When BIKTARVY Combination Tablets are administered and the multiplication of HIV in the blood is BIKTARVY Combination Tablets contain three active ingredients: bictegravir, emtricitabine, suppressed, immune-compromised patients recover some of their immune function and are less likely to and tenofovir alafenamide. These active ingredients block the mechanisms involved in the acquire opportunistic infections2). multiplication of HIV, thereby suppressing the multiplication of the virus. There is more than Herpesvirus one viral multiplication mechanism, and it is more eective to block two or more mechanisms Note 1) Amount of virus in the blood infection Candida at the same time. This is why it is popular to administer two or more active ingredients at the esophagitis The amount of virus in the blood is represented by the viral count in 1 mL same time. BIKTARVY take to How / Tablets Combination Eects of plasma. It indicates the treatment start time and/or the eects of the anti-HIV medicines. The goal of treatment is to maintain a viral concentration that is below the detection limit over a long period of time. Note 2) Opportunistic infections Mycobacterium HIV Signifies infections caused by weakly pathogenic microorganisms that do avium complex (MAC) not cause infections in people with normal immune function. infection CCR5 inhibitor Integrase inhibitor Opportunistic infections include candida esophagitis, herpesvirus Precautions infection, and Mycobacterium avium complex (MAC) infection. Bictegravir Absorption/fusion CD4 receptor How to take BIKTARVY Combination Tablets Invasion Integration Take one tablet of BIKTARVY once a day, with or without food. DNA To avoid forgetting to take BIKTARVY, and to ensure that it is taken at a regular interval, consult your synthesis doctor and decide the time of administration. HIV RNA mRNA → p.10 “How to prevent missing a dose” Reverse transcription Assembly Budding/release What to do if you miss miss do if you to What a dose of BIKTARVY Tablets Combination Tablet of BIKTARVY and how to store BIKTARVY Combination Tablets Protein Protein synthesis degradation/ modification Non-nucleoside reverse BIKTARVY is a purple-brown tablet, as shown in the Top view Bottom view Side view transcriptase inhibitor CD4 cell Protease inhibitor pictures on the right (actual size). Nucleoside reverse Keep BIKTARVY Combination Tablets out of the transcriptase inhibitor HIV reverse transcriptase reach of children. Emtricitabine HIV protease Keep BIKTARVY Combination Tablets in the Tenofovir alafenamide Side eects HIV integrase prescribed container. 1 Leave the desiccant in the container (do not remove it). Store BIKTARVY Combination Tablets at room temperature, 2 away from moisture. To uncap the container of BIKTARVY Combination Tablets: Desiccant 1) While pressing down on the cap, 2) Twist the cap to the left. 3 4 information Additional What are BIKTARVY Combination Tablets? / Introduction of contents Table BIKTARVY is a medicine for HIV infection that suppresses the multiplication of the virus in the blood1). Eects of BIKTARVY Combination Tablets When BIKTARVY Combination Tablets are administered and the multiplication of HIV in the blood is BIKTARVY Combination Tablets contain three active ingredients: bictegravir, emtricitabine, suppressed, immune-compromised patients recover some of their immune function and are less likely to and tenofovir alafenamide. These active ingredients block the mechanisms involved in the acquire opportunistic infections2). multiplication of HIV, thereby suppressing the multiplication of the virus. There is more than Herpesvirus one viral multiplication mechanism, and it is more eective to block two or more mechanisms Note 1) Amount of virus in the blood infection Candida at the same time. This is why it is popular to administer two or more active ingredients at the esophagitis The amount of virus in the blood is represented by the viral count in 1 mL same time. BIKTARVY take to How / Tablets Combination Eects of plasma. It indicates the treatment start time and/or the eects of the anti-HIV medicines. The goal of treatment is to maintain a viral concentration that is below the detection limit over a long period of time. Note 2) Opportunistic infections Mycobacterium HIV Signifies infections caused by weakly pathogenic microorganisms that do avium complex (MAC) not cause infections in people with normal immune function. infection CCR5 inhibitor Integrase inhibitor Opportunistic infections include candida esophagitis, herpesvirus Precautions infection, and Mycobacterium avium complex (MAC) infection. Bictegravir Absorption/fusion CD4 receptor How to take BIKTARVY Combination Tablets Invasion Integration Take one tablet of BIKTARVY once a day, with or without food. DNA To avoid forgetting to take BIKTARVY, and to ensure that
Load more

Recommended publications
  • Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health
    Final decisions & reasons for decisions by delegates of the Secretary to the Department of Health 29 June 2017 (ACMS and ACCS meetings – March 2017) Notice under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations) The delegates of the Secretary to the Department of Health hereby give notice of delegates’ final decisions for amending the Poisons Standard (commonly referred to as the Standard for the Uniform Scheduling of Medicines and Poisons - SUSMP) under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). This notice also provides the reasons for each decision and the date of effect (implementation date) of the decision. The delegates’ final decisions and reasons relate to: · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Medicines Scheduling (ACMS#20); · scheduling proposals initially referred to the March 2017 Joint meeting of the Advisory Committees on Chemicals and Medicines Scheduling (ACCS-ACMS#15); · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Chemicals Scheduling (ACCS#19); and · scheduling proposals considered as delegate-only matters, i.e. not referred to an expert advisory committee. Scheduling proposals referred to the expert advisory committees. Pre-meeting public notices On 22 December 2016 and 3 February 2017, under subsection 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations), the delegate published pre-meeting public notices on the TGA website which specified the proposed amendments to the current Poisons Standard. The notices also invited public comment on the scheduling proposals referred to the expert advisory committees. The pre-meeting consultation periods were open for public comment for 20 business days and closed on 10 February 2017 and 3 March 2017, respectively.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • For People Taking DESCOVY® Combination Tablets
    Gran Tokyo South Tower, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616 Tokyo, 1-9-2Marunouchi,Chiyoda-ku, South Tower, Tokyo Gran Inc. Gilead Sciences, Contact Information Contact DVY19DS0099PA Created in December 2019 inDecember Created DVY19DS0099PA CombinationTablets TakingDESCOVY National CenterforGlobalHealthandMedicine For People Director oftheAIDSClinicalCenter Shinichi Oka Editorial Supervisor ® Taking DESCOVY What to do if you miss How to take DESCOVY E ects of DESCOVY Introduction / Combination Tablets Side e ects a dose of DESCOVY during pregnancy / Combination Tablets / Combination Tablets Combination Tablets Table of contents Additional information Precautions Introduction For People Taking DESCOVY Combination Tablets Table of contents / Introduction of contents Table This leaflet was created for people who take DESCOVY Combination Tablets. This leaflet includes information about the characteristics of DESCOVY 01 Introduction Combination Tablets, how to take DESCOVY Combination Tablets, what to do if 3 What are DESCOVY Combination Tablets? DESCOVY you forget to take DESCOVY Combination Tablets, the side eects of DESCOVY Characteristics of DESCOVY Combination Tablets Combination Tablets, and precautions for taking DESCOVY Combination Tablets. E ects of DESCOVY Combination Tablets E ects of E ects Tablets Combination Read this leaflet thoroughly before taking DESCOVY Combination Tablets. 5 How should DESCOVY Combination Tablets be taken? Concomitant use of DESCOVY Combination Tablets with other medicines A medical decision needs to be made based on your circumstances before starting the administration of DESCOVY Combination Tablets. 9 What should you do if you miss a dose of DESCOVY Combination Tablets? Listen carefully to the explanation provided by your healthcare providers (physicians, nurses and pharmacists) and follow their instructions.
    [Show full text]
  • Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patien
    1 2 3 PROJECT TITLE 4 Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent 5 Patients in Critical Care 6 7 STUDY ACRONYM 8 Cytomegalovirus Control in Critical Care - CCCC 9 10 APPLICANTS 11 Dr Nicholas Cowley 12 Specialty Registrar Anaesthesia and Intensive Care Medicine, Intensive Care Research Fellow 13 Queen Elizabeth Hospital Birmingham 14 15 Professor Paul Moss 16 Professor of Haematology 17 Queen Elizabeth Hospital Birmingham 18 19 Professor Julian Bion 20 Professor of Intensive Care Medicine 21 Queen Elizabeth Hospital Birmingham 22 23 Trial Virologist Trial Statistician 24 Dr H Osman Dr P G Nightingale 25 Queen Elizabeth Hospital Birmingham University of Birmingham CCCC CMV Protocol V1.7, 18th September 2013 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 26 CONTENTS 27 Substantial Amendment Sept 18th 2013 4 28 1 SUMMARY OF TRIAL DESIGN .......................................................................................................... 5 29 2 QEHB ICU Duration of Patient Stay ................................................................................................. 6 30 3 SCHEMA - QEHB PATIENT NUMBERS AVAILABLE FOR RECRUITMENT ........................................... 6 31 4 INTRODUCTION ............................................................................................................................... 7 32 4.1 CMV latent infection is widespread ........................................................................................ 7 33 4.2 CMV Reactivation
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • SEXUALLY TRANSMITTED INFECTIONS GUIDANCE GENERAL POINTS • This Guidance Appli Es to ADULT Pati Ents ONLY • STOP and Think Before You Prescribe Antibiotics
    SEXUALLY TRANSMITTED INFECTIONS GUIDANCE GENERAL POINTS • This guidance appli es to ADULT pati ents ONLY • STOP and think before you prescribe antibiotics. Does your patient actually have an infection that requires treatment? • Normal renal and hepatic function assumed – adj us t dos es i f necessary. • For pregnant patients refer to Pr egna nc y a nd Pos tna tal Antibi oti c Woman • For all other infections refer to Hospital Antibiotic Man or Primary Care Antibiotic Man or Antibiotic Website • Refer to Mi croMan for ‘Anti biotic Rul es of Thumb’ and basic mi crobi ol ogy i nformati on on common infecti ons • Guidance on taking sexual history, testing and referral criteria is available in TSRH Primary Care Guidance p4 (add link) Chlamydia (uncomplicated) Doxycycline 100mg bd (7 days). If intolerant: azithromycin 1g od day 1 then 500mg od for 2 days Gonorrhoea Refer to Sexual and Reproductive Health Service. If patient will not attend contact TSRH team for advice. Gonorrhoea (sexual contacts) A full sexual health screen should be offered but antimicrobial treatment should not be prescribed without testing. Antimicrobial resistance is very high. Vulvovaginal candidiasis Fluconazole 150mg as a single dose plus clotrimazole 1% cream 2-3 times daily or Clotrimazole 500mg FEMALE pessary stat plus clotrimazole 1% cream 2-3 times daily Recurrent : >4 episodes/year - send HVS ma rke d “re cu rrent thrush” to microbiology and consider referral to Genito-Urinary Medicine if need advice on further management. Exclude predisposing factors. Bacterial
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports December 17, 2010 / Vol. 59 / No. RR-12 Sexually Transmitted Diseases Treatment Guidelines, 2010 department of health and human services Centers for Disease Control and Prevention MMWR CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 1 and Human Services, Atlanta, GA 30333. Clinical Prevention Guidance ..................................................... 2 STD/HIV Prevention Counseling ............................................... 2 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR 2010;59(No. RR-#):[inclusive page numbers]. Prevention Methods ................................................................ 4 Partner Management .............................................................. 7 Centers for Disease Control and Prevention Reporting and Confidentiality .................................................. 8 Thomas R. Frieden, MD, MPH Special Populations ................................................................... 8 Director Pregnant Women ................................................................... 8 Harold W. Jaffe, MD, MA Adolescents .........................................................................
    [Show full text]
  • Data Sheet Template
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME DBL™ Aciclovir Intravenous Infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DBL™ Aciclovir Intravenous Infusion contains the equivalent of 25 mg/mL of aciclovir; the aciclovir is present as aciclovir sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for Infusion DBL™ Aciclovir Intravenous Infusion is a clear colourless or almost colourless sterile solution. DBL™ Aciclovir Intravenous Infusion has a pH of approximately 11. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications DBL™ Aciclovir Intravenous Infusion is indicated for the treatment of Herpes simplex infections. DBL™ Aciclovir Intravenous Infusion is indicated for the prophylaxis of Herpes simplex infections in immune-compromised patients. DBL™ Aciclovir Intravenous Infusion is indicated in the treatment of Varicella zoster infections. DBL™ Aciclovir Intravenous Infusion is indicated for the treatment of Herpes simplex infections in the neonate. DBL™ Aciclovir Intravenous Infusion formulations are indicated for prophylaxis of CMV infection in bone marrow transplant recipients. It has been shown that high dose intravenous aciclovir reduces the incidence and delays the onset of CMV infection. When high dose intravenous aciclovir is followed by 6 months treatment with high dose oral aciclovir (see prescribing information for oral aciclovir) mortality and the incidence of viraemia are also reduced. Version 6.0 Page 1 of 10 4.2 Dose and method of administration Dosage in adults Patients with Herpes simplex (except herpes encephalitis) or Varicella zoster infections should be given DBL™ Aciclovir Intravenous Infusion in doses of 5 mg/kg bodyweight every 8 hours. Immune-compromised patients with Varicella zoster infections or patients with herpes encephalitis should be given DBL™ Aciclovir Intravenous Infusion in doses of 10 mg/kg bodyweight every 8 hours provided renal function is not impaired.
    [Show full text]
  • Revista6vol86v6 ING Layout 1
    1185 CASE REPORT ▲ Hypertrophic perianal herpes successfully treated with imiquimod * Herpes hipertrófico perianal tratado eficazmente com imiquimod Sara Isabel Alcântara Lestre1 Alexandre João2 Célia Carvalho3 Vasco Vieira Serrão2 Abstract: Herpes simplex virus type 2 (HSV-2) infections are frequent in HIV (human immunodeficiency virus) infected patients. In those cases, genital herpes may have an atypical clinical presentation. Hypertrophic and vegetating variants are unusual. The authors describe a case of hypertrophic perianal herpes in an HIV patient with unsatisfactory response to acyclovir and valacyclovir, successfully treated with imiquimod. Hypertrophic genital herpes cases are frequently refractory to antiviral treatments. In our experience, imiquimod is an efficient, safe and well tolerated treatment that should be considered in therapeutic approach of these patients. Keywords: Antiviral agents; Combined modality therapy; Efficacy; Herpes genitalis; Herpesvirus 2, human Resumo: A infecção pelo vírus herpes simples tipo 2 (HSV-2) é frequente em pacientes infetados pelo vírus de imunodeficiência adquirida (VIH). Nestes casos, o herpes genital pode ter uma apresentação clínica atí- pica. As variantes hipertróficas e vegetantes são pouco habituais. Os autores relatam um caso de herpes hipertrófico perianal em paciente infetada pelo VIH, com resposta insatisfatória ao aciclovir e valaciclovir, tratado eficazmente com imiquimod tópico. O herpes genital hipertrófico é, frequentemente, refratário aos tratamentos antivirais. Na nossa
    [Show full text]
  • Adult Treatment of Infection Guidelines
    GP ADULT Empirical Treatment of Infection Guidance • STOP AND THINK BEFORE YOU PRESCRIBE ANTIBIOTICS DOES YOUR PATIENT ACTUALLY HAVE AN INFECTION AND REQUIRE TREATMENT? • TO REDUCE EMERGENCE OF RESISTANCE AND CLOSTRIDIUM DIFFICILE INFECTION USE NARROW SPECTRUM ANTIBIOTICS WHEREVER POSSIBLE AND IN PARTICULAR AVOID CIPROFLOXACIN AND OTHER QUINOLONES, CEPHALOSPORINS AND CO-AMOXICLAV • LIMIT PRESCRIBING OVER THE TELEPHONE TO EXCEPTIONAL CIRCUMSTANCES • CONSIDER A ‘NO PRESCRIBING’ OR ‘DELAYED PRESCRIBING’ STRATEGY FOR UPPER RESPIRATORY TRACT INFECTIONS • FULL GUIDANCE IS AVAILABLE IN TAYSIDE AREA PRESCRIBING GUIDE SECTION 16 (www.nhstaysideadtc.scot.nhs.uk or LINK ON STAFFNET HOME PAGE) MENINGITIS Give dose of Benzylpenicillin (IV/IM) 1.2g or Chloramphenicol (IV) 1g then transfer to hospital immediately. CNS: Health Protection Team will deal with prophylaxis for family and contacts. ORBITAL CELLULITIS Medical emergency – transfer to hospital immediately. CONJUNCTIVITIS Usually self-limiting. If necessary use chloramphenicol eye drops 2 hourly reducing to 4 times daily + EYE: ointment at night or ointment alone 3-4 times daily. Continue for 48 hours after resolution. OPTHALMIC SHINGLES Refer to Opthalmology. Aciclovir 800mg 5 times daily or Valaciclovir 1g tds ( 7 days) + Aciclovir eye oint DENTAL ABSCESS Penicillin V 500mg-1g qds or Amoxicillin 250-500mg tds or Metronidazole 200mg tds (5 days) ST ND DENTAL: PERICORONITIS 1 LINE Metronidazole 200mg tds (3 days) 2 LINE Amoxicillin 250-500mg tds (3 days) Refer to GDP ULCERATIVE GINGIVITIS Metronidazole 200mg tds (3 days) TONSILLITIS/ Av. length illness 1 week. Most are viral. PHARYNGITIS/ If 3 or 4 of centor criteria (fever, purulent tonsils, cervical lymphadenopathy, no cough) or history of otitis media then SORE THROAT antibiotics may be of more benefit.
    [Show full text]
  • Aciclovir 800 Mg Tablets Bp
    Package leaflet: Information for the user Aciclovir 800 mg Tablets Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Aciclovir 800 mg Tablets are and what they are used for 2. What you need to know before you take Aciclovir 800 mg Tablets 3. How to take Aciclovir 800 mg Tablets 4. Possible side effects 5. How to store Aciclovir 800 mg Tablets 6. Contents of the pack and other information 1. What Aciclovir 800 mg Tablets are and what they are used for Aciclovir 800 mg Tablets contain a medicine called aciclovir. This belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses. Aciclovir can be used to • treat chickenpox and shingles • treat cold sores, genital herpes and other herpes simplex infections • stop these problems returning after you have had them • stop these problems in people whose immune system works less well, which means their bodies are less able to fight infections. 2. What you need to know before you take Aciclovir 800 mg Tablets Do not take Aciclovir 800 mg Tablets: − if you are allergic to aciclovir or valaciclovir or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]